EA029416B1 - Таблетка, содержащая иматиниб или его фармацевтически приемлемую соль, и способ ее получения - Google Patents

Таблетка, содержащая иматиниб или его фармацевтически приемлемую соль, и способ ее получения Download PDF

Info

Publication number
EA029416B1
EA029416B1 EA201300034A EA201300034A EA029416B1 EA 029416 B1 EA029416 B1 EA 029416B1 EA 201300034 A EA201300034 A EA 201300034A EA 201300034 A EA201300034 A EA 201300034A EA 029416 B1 EA029416 B1 EA 029416B1
Authority
EA
Eurasian Patent Office
Prior art keywords
tablet
pharmaceutically acceptable
imatinib
acceptable salt
disintegrant
Prior art date
Application number
EA201300034A
Other languages
English (en)
Russian (ru)
Other versions
EA201300034A1 (ru
Inventor
Сайсива Прасад Равула
Ананд Кумар Мамиди
Original Assignee
Заклады Фармацеутицне Польфарма Са
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Заклады Фармацеутицне Польфарма Са filed Critical Заклады Фармацеутицне Польфарма Са
Publication of EA201300034A1 publication Critical patent/EA201300034A1/ru
Publication of EA029416B1 publication Critical patent/EA029416B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EA201300034A 2010-06-21 2011-06-17 Таблетка, содержащая иматиниб или его фармацевтически приемлемую соль, и способ ее получения EA029416B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN1732CH2010 2010-06-21
EP10460039 2010-09-20
PCT/EP2011/003020 WO2011160798A1 (en) 2010-06-21 2011-06-17 Pharmaceutical compositions comprising imatinib or pharmaceutically acceptable salt thereof and processes for the manufacture thereof

Publications (2)

Publication Number Publication Date
EA201300034A1 EA201300034A1 (ru) 2013-05-30
EA029416B1 true EA029416B1 (ru) 2018-03-30

Family

ID=44358103

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201300034A EA029416B1 (ru) 2010-06-21 2011-06-17 Таблетка, содержащая иматиниб или его фармацевтически приемлемую соль, и способ ее получения

Country Status (4)

Country Link
EP (1) EP2582362A1 (pl)
EA (1) EA029416B1 (pl)
PL (1) PL234542B1 (pl)
WO (1) WO2011160798A1 (pl)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9750700B2 (en) * 2011-06-22 2017-09-05 Natco Pharma Limited Imatinib mesylate oral pharmaceutical composition and process for preparation thereof
JP5928159B2 (ja) * 2012-05-28 2016-06-01 ニプロ株式会社 医薬組成物
EP2749271A1 (en) * 2012-12-31 2014-07-02 Deva Holding Anonim Sirketi Optimized manufacturing method and pharmaceutical formulation of imatinib
GB201304699D0 (en) * 2013-03-15 2013-05-01 Remedica Ltd Pharmaceutical compositions
EP2803353B1 (en) 2013-05-14 2018-05-23 Hetero Research Foundation Compositions of Imatinib
CN104414988B (zh) * 2013-08-28 2018-07-06 山东新时代药业有限公司 一种达沙替尼片剂及其制备工艺
EA035891B1 (ru) * 2016-01-25 2020-08-27 КРКА, д.д., НОВО МЕСТО Быстродиспергируемая фармацевтическая композиция, включающая ингибитор тирозинкиназы
EP3257499A1 (en) 2016-06-17 2017-12-20 Vipharm S.A. Process for preparation of imatinib methanesulfonate capsules
CN107648237B (zh) * 2016-07-26 2022-03-04 江苏豪森药业集团有限公司 氨基嘧啶类化合物的药物组合物及其制备方法
WO2019016673A2 (en) * 2017-07-20 2019-01-24 Kashiv Pharma Llc STABLE PHARMACEUTICAL COMPOSITION OF ORAL ADMINISTRATION OF IMATINIB
EP3999063A1 (en) * 2019-07-15 2022-05-25 Novartis AG Formulations of (s)-3-amino-6-methoxy-n-(3,3,3-trifluoro-2-hydroxy-2-methylpropyl)-5-(trifluoromethyl)picolinamide

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0564409A1 (de) * 1992-04-03 1993-10-06 Ciba-Geigy Ag Pyrimidinderivate und Verfahren zu ihrer Herstellung
EP1762230A1 (de) * 2005-08-15 2007-03-14 Siegfried Generics International AG Filmtablette oder Granulat enthaltend ein Pyridylpyrimidin
EP1501485B1 (en) * 2002-04-23 2007-09-26 Novartis AG High drug load tablet
US20090087489A1 (en) * 2007-09-25 2009-04-02 Bella Gerber Imatinib compositions

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0564409A1 (de) * 1992-04-03 1993-10-06 Ciba-Geigy Ag Pyrimidinderivate und Verfahren zu ihrer Herstellung
EP1501485B1 (en) * 2002-04-23 2007-09-26 Novartis AG High drug load tablet
EP1762230A1 (de) * 2005-08-15 2007-03-14 Siegfried Generics International AG Filmtablette oder Granulat enthaltend ein Pyridylpyrimidin
US20090087489A1 (en) * 2007-09-25 2009-04-02 Bella Gerber Imatinib compositions

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
"Pharmaceutical compositions containing Imatinib", RESEARCH DISCLOSURE, KENNETH MASON PUBLICATIONS, HAMPSHIRE, UK, GB, vol. 542, no. 6, 542006, 1 June 2009 (2009-06-01), GB, pages 573, XP007139052, ISSN: 0374-4353 *
"Stable Tablet Formulation containing more than 80% of Imatinib mesylate", IP.COM JOURNAL, IP.COM INC., WEST HENRIETTA, NY, US, 19 February 2008 (2008-02-19), XP013123894, ISSN: 1533-0001 the whole document *

Also Published As

Publication number Publication date
EA201300034A1 (ru) 2013-05-30
EP2582362A1 (en) 2013-04-24
WO2011160798A1 (en) 2011-12-29
PL234542B1 (pl) 2020-03-31
PL402710A1 (pl) 2013-09-30

Similar Documents

Publication Publication Date Title
EA029416B1 (ru) Таблетка, содержащая иматиниб или его фармацевтически приемлемую соль, и способ ее получения
RU2363450C2 (ru) Таблетка с высоким содержанием лекарственного препарата
EP1810676B1 (en) Levetiracetam formulations and methods for their manufacture
KR101977785B1 (ko) 에제티미브 및 로수바스타틴을 포함하는 경구용 복합제제 및 그 제조방법
KR20230097211A (ko) 루카파립의 고 용량 강도 정제
KR20090016611A (ko) 메만틴의 약학 조성물
EA023972B1 (ru) Стабильный твёрдый препарат карипразина для перорального введения и способ его получения
CA2662265A1 (en) Imatinib compositions
EP3606511B1 (en) Pharmaceutical composition comprising lenvatinib mesylate
KR20160058763A (ko) 암로디핀 및 발사르탄를 함유하는 안정적인 약제학적 조성물
AU2019232937B2 (en) Ceritinib formulation
JP7428356B2 (ja) 高いバイオアベイラビリティを有するソラフェニブの医薬組成物、ソラフェニブ経口固形製剤、及びその使用
EP2497464A2 (en) Pharmaceutical composition of imatinibe methanesulphonate and a process for its manufacture
JP5575114B2 (ja) シュウ酸エスシタロプラムを含む粒状物
EP3860606B1 (en) Pharmaceutical composition comprising lenvatinib esylate or tosylate
WO2010046418A1 (en) Pharmaceutical composition comprising levetiracetam
KR101938872B1 (ko) 도네페질 또는 그의 약학적으로 허용 가능한 염 및 메만틴 또는 그의 약학적으로 허용 가능한 염을 함유하는 치매 및 인지기능 장애 예방 또는 치료용 약학 조성물 및 이의 제조방법
KR102622198B1 (ko) 빌다글립틴을 함유하는 경구용 고형제제 및 그의 제조 방법
KR101944085B1 (ko) 발사르탄 함유 고형 경구제형 및 그 제조방법
JP7362302B2 (ja) レベチラセタムを含有する錠剤とその製造方法
EP4260848A1 (en) Pharmaceutical composition for solid dosage form containing nilotinib and process for its preparation
WO2017078647A1 (en) Pharmaceutical compositions of imatinib
KR20180060705A (ko) 에제티미브 및 로수바스타틴을 포함하는 경구용 복합정제
RU2183119C1 (ru) Фармацевтическая композиция, обладающая спазмолитической активностью, способ ее получения
RU2289422C2 (ru) Фармацевтическая композиция на основе ноопепта

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU